人のウォール街のアナリストによると、Sequana Medical NVの収益見積もりは$から$の範囲です。
Sequana Medical NVの収益品質スコアはどれくらいですか?
Sequana Medical NVの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Sequana Medical NVはいつ収益を報告しますか?
Sequana Medical NVの次の収益報告は2026-06-23に予定されています
Sequana Medical NVの予想収益はいくらですか?
ウォール街のアナリストによると、Sequana Medical NVの予想収益は$515.0Kです。
Sequana Medical NVは収益予想を上回りましたか?
Sequana Medical NVの最近の収益は$で、予想を。
主要データ
前終値
--
始値
--
当日レンジ
-
52週レンジ
$0.78 - $3
取引高
--
平均取引高
350
配当利回り
--
1株当たり利益(TTM)
--
時価総額
$83.0M
SEQUANA MEDICAL NVとは何ですか?
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.